C8 MediSensors, a US-based diabetes treatment company backed by US-based conglomerate General Electric, has raised $19m.
The funding will help C8 MediSensors launch in Europe. C8 MediSensors said its “leading investors” participated in the round.
C8 MediSensors uses light, in a process called Raman spectroscopy, to allow diabetics to measure glucose in a monitor.
C8 Medisensors secured $24m in its series C funding last year investors including General Electric’s GE Capital financial services division and its GE Healthcare division, which…
